Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 9 ... novel drugs including bendamustine, a unique cytostatic with combined properties of an alkylating agent and purine analog, the monoclonal antibodies anti-CD20 ofatumumab and the anti-CD23 ...
2009 SEP 28 ... outside of the U.S. for the treatment of B-CLL in patients who have been treated with alkylating agents and for whom fludarabine combination therapy is not appropriate. The product was ... Campath® (alemtuzumab) Alemtuzumab is licensed in the United States as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), and outside of the ...
2009 OCT 12 ... as a second-line therapy for B-CLL patients who have failed previous treatment with alkylating agents. In addition, Fludara i.v. has been approved as a first-line therapy of B-CLL in ... Genzyme Transplant and Oncology. "Campath has proven to be a highly active single agent therapy across the spectrum of this disease, and Fludara is considered a backbone of CLL ...
2009 OCT 19 ... "Laromustine (VNP40101M, also known as Cloretazine) is a novel sulfonylhydrazine alkylating ( anticancer) agent. Laromustine generates two types of reactive intermediates: 90CE and ...
2009 AUG 31 ... (NTR) into the virus HSV1716. NTR converts the prodrug CB1954 into an active alkylating agent." "In vitro, 3T6 cells (non permissive to HSV) were used in order to ...
2009 SEP 21 ... is a clinical chemotherapeutic equivalent requiring metabolic breakdown to the alkylating agent. Both chemicals have similar mechanistic efficacy against DNA mismatch repair-proficient ...
2009 NOV 9 ... "The acid is esterified by an alkyl halide i.e. benzyl bromide as the alkylating agent for perfluorocarboxylic acids quantification in fish and water by GC/MS. The gas ...
2009 AUG 24 ... to investigate the expression of genes involved in apoptotic cell death induced by an alkylating agent. Using RNA interference, we determined the roles of PARP-1 and PARP-2 in transcriptional ...
2009 OCT 5 ... damage survival, we used a cell-based RNAi screen against the Drosophila genome and the alkylating agent methyl methanesulphonate (MMS)," researchers in the United States report. ...
2009 SEP 29 ... absence, its insertion into liposomes is inhibited by the thiol oxidant diamide and the alkylating agent N-ethylmaleimide. The effect of diamide is also observed in living cells," wrote S.F. ...
2009 OCT 5 ... cytoreduction (n = 19; 32.6 vs 14.5 months, P = 0.14). The combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. The prognosis of ...
2009 OCT 19 ... "Chlorambucil (N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid) is a bifunctional alkylating drug belonging to the nitrogen mustard group and is widely used as ail anticancer agent. ...
2009 SEP 28 ... "Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the ...
2009 OCT 12 ... advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With ...
2009 NOV 25 ... formation of isopropyl xylenes (dimethyl cumenes). However, the use of propylene as an alkylating agent at very high temperatures leads to coke formation, which results in deactivation of the ...
2009 NOV 1 ... the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating drugs used to treat certain cancers. Palifosfamide does not have the toxic metabolites ... setting. Patients are randomized either to doxorubicin (the current only FDA approved agent in sarcoma) or to palifosfamide in combination with doxorubicin. A total of 58 patients ...
2009 OCT 12 ... the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating drugs used to treat certain cancers. Palifosfamide does not have the toxic metabolites ... Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Indibulin is expected to have ...
2009 NOV 23 ... the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating drugs used to treat certain cancers. Palifosfamide does not have the toxic metabolites ... setting. Patients are randomized either to doxorubicin (the only currently FDA-approved agent in sarcoma) or to palifosfamide in combination with doxorubicin. As of the October 5th ...
2009 NOV 23 ... the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating drugs used to treat certain cancers. Palifosfamide does not have the toxic metabolites ... Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. Indibulin is expected to have ...
